Catalyst Event
Takeda Pharmaceutical Co Ltd (TAK) · Earnings Release
From KEDI Global Longevity Bio Index (KGLB)
5/13/2026, 12:00:00 AM
Takeda is scheduled to announce its financial results for the full fiscal year 2025 (ending March 31, 2026) on May 13, 2026. High importance is estimated as earnings reports for major pharmaceutical firms often trigger price movements exceeding 10% based on guidance. This event is scheduled.
Korean Translation
2026년 5월 13일, 2025 회계연도(2026년 3월 31일 종료) 전체 재무 실적 발표가 예정됨. 대형 제약사의 실적 발표는 가이던스에 따라 10% 이상의 주가 변동을 초래하는 경우가 많아 높은 중요도로 예상됨.
Related Recent Events
Biogen Inc (BIIB) · Other
FDA PDUFA target action date for LEQEMBI's subcutaneous autoinjector formulation (IQLIK SC-AI) for initiation dosing, a potential new administration option for the Alzheimer's disease treatment, scheduled for 2026-05-24. High impact expected due to the significant market potential of the Alzheimer's treatment.
5/24/2026, 12:00:00 AM
Thermo Fisher Scientific Inc (TMO) · Other
An Investor Day is scheduled for May 20, 2026, where senior management will provide presentations scheduled.
5/20/2026, 12:00:00 AM
Natera Inc (NTRA) · Earnings Release
Q1 2026 earnings release is scheduled. Earnings announcements typically result in >5% price impact, scheduled.
5/7/2026, 12:00:00 AM
Viatris Inc (VTRS) · Earnings Release
Viatris is scheduled to report its first quarter 2026 financial results on May 7, 2026, with an estimated price impact of over 5% based on historical earnings volatility scheduled.
5/7/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Earnings Release
Novo Nordisk is scheduled to announce its first quarter 2026 financial results. Low importance as it is a routine earnings call, scheduled.
5/6/2026, 12:00:00 AM
Revvity Inc (RVTY) · Earnings Release
Revvity will release its Q1 2026 financial results before market open on May 5, 2026, with a conference call scheduled for 7:30 a.m. ET. High importance is estimated as earnings reports typically drive significant price movements scheduled
5/5/2026, 12:00:00 AM